{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=70", "query": { "intervention": "Normal protein", "page": 70 }, "page_size": 10 }, "pagination": { "page": 70, "page_size": 10, "total_count": 2508, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=71&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=69&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T20:20:49.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03816345", "title": "Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Disease", "Crohn Disease", "Dermatomyositis", "Hematopoietic and Lymphoid Cell Neoplasm", "Inflammatory Bowel Disease", "Malignant Solid Neoplasm", "Multiple Sclerosis", "Psoriasis", "Psoriatic Arthritis", "Rheumatoid Arthritis", "Sjogren Syndrome", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Ulcerative Colitis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Fluoropyrimidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-07-16", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816345" }, { "nct_id": "NCT01527045", "title": "Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Blasts Under 5 Percent of Bone Marrow Nucleated Cells", "Chronic Lymphocytic Leukemia", "Loss of Chromosome 17p", "Myelodysplastic/Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Aggressive Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Atorvastatin Calcium", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2012-09-25", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 2, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527045" }, { "nct_id": "NCT06237465", "title": "Botulinum Toxin-A for Hidradenitis Suppurativa", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hidradenitis Suppurativa", "Hidradenitis Suppurativa \\(HS\\)", "Hidradenitis Suppurativa, Acne Inversa" ], "interventions": [ { "name": "Normal saline", "type": "DRUG" }, { "name": "Botulinum toxin type A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-01", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 1, "location_summary": "Guilford, Connecticut", "locations": [ { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06237465" }, { "nct_id": "NCT02223429", "title": "Neurobiological Bases of Paternal Nurturance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Oxytocin", "type": "DRUG" }, { "name": "Vasopressin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James K. Rilling, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02223429" }, { "nct_id": "NCT00056654", "title": "Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Leuprolide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 164, "start_date": "2003-03", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2008-09-17", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 55, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056654" }, { "nct_id": "NCT02188719", "title": "Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Transplantation" ], "interventions": [ { "name": "Anti-Thymocyte Globulin - Rabbit", "type": "BIOLOGICAL" }, { "name": "darTreg Infusion", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Anti-Infective Prophylaxis", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Blood draws", "type": "PROCEDURE" }, { "name": "Liver biopsies", "type": "PROCEDURE" }, { "name": "Liver transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2014-12-17", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188719" }, { "nct_id": "NCT03656692", "title": "Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Uveitis, Posterior", "Uveitis, Intermediate", "Panuveitis" ], "interventions": [ { "name": "Acthar Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-10-05", "completion_date": "2020-07-14", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 8, "location_summary": "Clearwater, Florida • Indianapolis, Indiana • Waltham, Massachusetts + 5 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Waltham", "state": "Massachusetts" }, { "city": "Palisades Park", "state": "New Jersey" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656692" }, { "nct_id": "NCT00255710", "title": "Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2002-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-17", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00255710" }, { "nct_id": "NCT07880860", "title": "Cleft Lip Scarring After Botox", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cleft Lip", "Cleft Lip Scar" ], "interventions": [ { "name": "Botulinum Toxin Type A (BOTOX) Injection", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "12 Months", "sex": "ALL", "summary": "0 Days to 12 Months" }, "enrollment_count": 40, "start_date": "2026-02-19", "completion_date": "2032-02", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07880860" }, { "nct_id": "NCT00116220", "title": "Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Flutamide (Eulexin) and Lupron or Zoladex", "type": "DRUG" }, { "name": "External Beam Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "41 Years", "maximum_age": null, "sex": "MALE", "summary": "41 Years and older · Male only" }, "enrollment_count": 206, "start_date": "1995-09", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2022-01-06", "last_synced_at": "2026-11-06T20:20:49.901Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116220" } ] }